Molecular Landscape and Validation of New Genomic Classification in 2668 Adult AML Patients: Real Life Data from the PETHEMA RegistryClaudia Sargas, Juan Bergua, Lorenzo Algarra et al.|Cancers|2023Cited by 30
Comparison of the 2022 and 2017 European LeukemiaNet risk classifications in a real-life cohort of the PETHEMA groupClaudia Sargas, Rosa Ayala, María José Larráyoz et al.|Blood Cancer Journal|2023Cited by 28
Impact of FLT3–ITD Mutation Status and Its Ratio in a Cohort of 2901 Patients Undergoing Upfront Intensive Chemotherapy: A PETHEMA Registry StudyRosa Ayala, Pau Montesinos, Gonzalo Carreño‐Tarragona et al.|Cancers|2022Cited by 12
Evolving patterns and clinical outcome of genetic studies performed at diagnosis in acute myeloid leukemia patients: Real life data from the PETHEMA RegistryJorge Labrador, David Martínez‐Cuadrón, Blanca Boluda et al.|Cancer|2024Cited by 5
Conventional PCR Versus Next Generation Sequencing for Diagnosis of FLT3, IDH and NPM1 Mutations in Acute Myeloid Leukemia: Results of the PETHEMA PCR-LMA StudyBlanca Boluda, Pau Montesinos, Rebeca Rodríguez‐Veiga et al.|Cancers|2025Cited by 2